CO4700482A1 - Formulaciones de un analogo monomero de insulina - Google Patents

Formulaciones de un analogo monomero de insulina

Info

Publication number
CO4700482A1
CO4700482A1 CO96015449A CO96015449A CO4700482A1 CO 4700482 A1 CO4700482 A1 CO 4700482A1 CO 96015449 A CO96015449 A CO 96015449A CO 96015449 A CO96015449 A CO 96015449A CO 4700482 A1 CO4700482 A1 CO 4700482A1
Authority
CO
Colombia
Prior art keywords
physiologically acceptable
insulin analog
solution
analog
ppm
Prior art date
Application number
CO96015449A
Other languages
English (en)
Inventor
Felippis Michael Rosario De
Hill Frank Bruce
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4700482A1 publication Critical patent/CO4700482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica parenteral que tiene un efectoprolongado, que consiste esencialmente en una suspensión acuosa estéril de aproximadamente 20 U/ml a aproximadamente 500 U/ml de un análogo de insulina, aproximadamente de 5 mg/ml a aproximadamente 10 mg/ml de cloruro sódico, aproximadamente 0,2 a aproximadamente 2,0 mg/ml de un tampón fisiológicamente aceptable, un contenido de iones zinc de aproximadamente 0,04 mg/ml a aproximadamente 20,0 mg/ml y un conservante fisiológicamente aceptable, a un pH de aproximadamente 6,5 a aproximadamente 7,8; tal que menos de 5% del análogo presente en la suspensión está en estado disuelto. 1Un procedimiento para preparar cristales de insulina humana-LysB28 ProB29 , que comprende combinar: una primera solución que comprende aproximadamente 300 U/ml a aproximadamente 2.000 U/ml del análogo de insulina, aproximadamente 500 ppm a aproximadamente 3.000 ppm de fenol y un exceso molar de iones zinc, a un pH de aproximadamente 2,0 a aproximadamente 3,0, y una segunda solución que comprende aproximadamente 130 mg/ml a aproximadamente 270 mg/ml de cloruro sódico y aproximadamente 5,0 a aproximadamente 55,0 mg/ml de un tampón fisiológicamente aceptable, a un pH de aproximadamente 10,5 a 12,5, de modo que el pH de la solución combinada sea de 5,0 a 6,0.
CO96015449A 1995-03-31 1996-03-28 Formulaciones de un analogo monomero de insulina CO4700482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41488095A 1995-03-31 1995-03-31

Publications (1)

Publication Number Publication Date
CO4700482A1 true CO4700482A1 (es) 1998-12-29

Family

ID=23643384

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96015449A CO4700482A1 (es) 1995-03-31 1996-03-28 Formulaciones de un analogo monomero de insulina

Country Status (23)

Country Link
US (1) US5952297A (es)
EP (1) EP0735048A1 (es)
JP (1) JPH11502856A (es)
KR (1) KR19980703425A (es)
CN (1) CN1185114A (es)
AR (1) AR002976A1 (es)
AU (1) AU720300B2 (es)
BR (1) BR9607935A (es)
CA (1) CA2216516A1 (es)
CO (1) CO4700482A1 (es)
CZ (1) CZ305297A3 (es)
EA (1) EA000970B1 (es)
HU (1) HUP9801700A3 (es)
IL (1) IL117696A (es)
MX (1) MX9707428A (es)
NO (1) NO974498L (es)
NZ (1) NZ305719A (es)
PE (1) PE38797A1 (es)
PL (1) PL322626A1 (es)
TR (1) TR199701078T1 (es)
WO (1) WO1996030040A1 (es)
YU (1) YU18596A (es)
ZA (1) ZA962502B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
PE79099A1 (es) * 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
WO1999048520A1 (en) * 1998-03-24 1999-09-30 Joergensen Klavs Holger Novel preparation of protracted acting human insulin
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
CA2431033A1 (en) * 2001-02-09 2002-08-22 Genentech, Inc. Crystallization of igf-1
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
MA33064B1 (fr) 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
CN102686260B (zh) 2009-11-25 2014-10-01 贝林格尔.英格海姆国际有限公司 喷雾器
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
TWI608847B (zh) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
ES2954961T3 (es) 2014-05-07 2023-11-27 Boehringer Ingelheim Int Unidad, nebulizador y método
US10716907B2 (en) 2014-05-07 2020-07-21 Boehringer Ingelheim International Gmbh Nebulizer
PL3139984T3 (pl) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizator
WO2016007682A1 (en) * 2014-07-08 2016-01-14 Amphastar Pharmaceuticals Inc. Micronized insulin, micronized insulin analogues, and methods of manufacturing the same
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10322168B2 (en) * 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
BR112022019687A2 (pt) 2020-03-31 2022-12-20 Protomer Tech Inc Conjugados para responsividade seletiva a dióis vicinais
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2648622A (en) * 1950-11-29 1953-08-11 Research Corp Purifying insulin by seeding with unclumped fibrils of insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
AT304760B (de) * 1969-08-08 1973-01-25 Novo Terapeutisk Labor As Verfahren zur Reinigung von Insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
EP0735048A1 (en) 1996-10-02
TR199701078T1 (xx) 1998-01-21
NO974498D0 (no) 1997-09-29
KR19980703425A (ko) 1998-11-05
EA199700285A1 (ru) 1998-02-26
AU5381296A (en) 1996-10-16
ZA962502B (en) 1997-09-29
CA2216516A1 (en) 1996-10-03
NO974498L (no) 1997-10-08
AU720300B2 (en) 2000-05-25
EA000970B1 (ru) 2000-08-28
IL117696A (en) 2000-01-31
PL322626A1 (en) 1998-02-02
CN1185114A (zh) 1998-06-17
IL117696A0 (en) 1996-07-23
BR9607935A (pt) 1998-06-02
CZ305297A3 (cs) 1998-02-18
MX9707428A (es) 1997-12-31
HUP9801700A2 (hu) 1998-11-30
JPH11502856A (ja) 1999-03-09
PE38797A1 (es) 1997-10-04
YU18596A (sh) 1998-07-10
WO1996030040A1 (en) 1996-10-03
US5952297A (en) 1999-09-14
HUP9801700A3 (en) 1998-12-28
NZ305719A (en) 1998-09-24
AR002976A1 (es) 1998-05-27

Similar Documents

Publication Publication Date Title
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
KR100709148B1 (ko) 피부 노화나 손상을 치료하기 위한 아스코르브산 조성물및 방법
KR970706830A (ko) 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)
KR900015737A (ko) 배합물
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
AU4185696A (en) Increasing creatine and glycogen concentration in muscle
GEP19971155B (en) Contrast medium and method for its production
DE69131352T2 (de) Steigerung des glutathionspiegels durch glutamin
IE891118L (en) Topical preparation for treating otopathy
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
KR880005933A (ko) 비타민 b6-함유 약제학적 제제
CA2086565A1 (en) Pharmaceutical composition for treating pigmentation
US3230143A (en) Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
KR970706844A (ko) 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor)
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre
GB1460325A (en) Pharmaceutical composition intended for relieving pain and producing analgesia
Roth Jr et al. The effects of nitrogen and sulfur mustards on hemoglobin S and intact red cells
IT1244647B (it) Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.
ES2031930T3 (es) Un metodo para obtener una preparacion liofilizada que contiene aspoxicilina como ingrediente activo.
CA2120917A1 (en) External preparation for treating hemorrhoidal diseases
KR900017599A (ko) 종양 치료용 약학 조성물
RU93055556A (ru) Препарат для лечения мастита крупного рогатого скота "лизомаст"